Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20549515 | 1.00 | NPC1 (0.31) | NPC1LMNARAB9ACDK1MAPKAPK2 | |
| SCHEMBL28517987 | 0.70 | MEN1 (0.46) | NPC1LMNARAB9ACDK1MAPKAPK2 | |
| SCHEMBL10841291 | 0.70 | AR (0.30) | — | |
| SCHEMBL10834821 | 0.69 | AR (0.43) | — | |
| SCHEMBL15231700 | 0.69 | CREBBP (0.46) | — | |
| SCHEMBL29070676 | 0.67 | CHRNB2 (0.36) | CDK1MAPKAPK2 | |
| SCHEMBL24290488 | 0.67 | PNMT (0.42) | NPC1LMNARAB9AMAPKAPK2 | |
| SCHEMBL16722791 | 0.67 | PNMT (0.42) | NPC1LMNARAB9AMAPKAPK2 | |
| SCHEMBL29070701 | 0.67 | HTR2C (0.40) | — | |
| SCHEMBL30570960 | 0.67 | HTR2C (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180318311-A1 | TRICYCLIC 2-QUINOLINONES AS ANTIBACTERIALS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2018-11-08 | — | — | US | disclosed |
| WO-2018203302-A1 | TRICYCLIC 2-QUINOLINONES AS ANTIBACTERIALS | NOVARTIS AG (CH) | 2018-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180318311-A1 | TRICYCLIC 2-QUINOLINONES AS ANTIBACTERIALS | TOP1, TOP2A, TOP2B | NPC1 2303/4885LMNA 1137/4885RAB9A 2307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.